Navigation Links
An end to fear
Date:3/11/2009

A team of Dutch researchers under the leadership of Vici-winner Merel Kindt has successfully reduced the fear response. They weakened fear memories in human volunteers by administering the beta-blocker propranolol. Interestingly, the fear response does not return over the course of time. Top journal Nature Neuroscience published the findings on 15 February 2009.

Until recently, it was assumed that the fear memory could not be deleted. However, Klindt's team has demonstrated that changes can indeed be effected in the emotional memory of human beings.

Storing changes

Before fear memories are stored in the long-term memory, there is a temporary labile phase. During this phase, protein synthesis takes place that 'records' the memories. The traditional idea was that the memory is established after this phase and can, therefore, no longer be altered. However, this protein synthesis also occurs when memories are retrieved from the memory and so there is once again a labile phase at that moment. The researchers managed to successfully intervene in this phase.

During their experiments the researchers showed images of two different spiders to the human volunteers. One of the spider images was accompanied by a pain stimulus and the other was not. Eventually the human volunteers exhibited a startle response (fear) upon seeing the first spider without the pain stimulus being administered. The anxiety for this spider had therefore been acquired.

One day later the fear memory was reactivated, as a result of which the protein synthesis occurred again. Just before the reactivation, the human volunteers were administered the beta-blocker propranolol. On the third day it was found that the volunteers who had been administered propranolol no longer exhibited a fear response on seeing the spider, unlike the control group who had been administered a placebo. The group that had received propranolol but whose memory was not reactivated still exhibited a strong startle response. The fear response was measured using two electrodes under the eye that measured the eye-blinking reflex. The response measured is one directly initiated by the amygdala, the emotional centre of the brain.

Searching in deleted items

Cognitive behavioural therapy is currently the prevailing and most effective method for treating anxiety disorders. During such a treatment the patient is exposed to the fear-eliciting stimulus without the feared consequence occurring. This method frequently only achieves short-term results and the fears often return over the course of time.

Interestingly, after the treatment with propranolol and memory reactivation, fear memories can no longer be recalled by means of a much-used method in which the individual pain stimuli are readministered. This indicates that the anxiety memory is either completely erased or could no longer be found in the memory. It should be noted, however, that the human volunteers could remember the association between the spider and the pain stimulus but that this no longer elicited any emotional response. In the next phase of the research, Kindt and her colleagues shall investigate the long-term effects of administering propranolol.

Treatment of anxiety disorders

The researchers expect that the results from this study can contribute to a new procedure for the treatment of patients with anxiety disorders. The method intervenes in the memory in a completely different way to conventional treatments. Whereas the traditional cognitive behavioural therapies frequently focus on the creation of new memories, this method focuses on the weakening of the existing emotional memory.

In 2007, Merel Kindt received a Vici grant from NWO for her innovative research. This study was carried out by Merel Kindt, Marieke Soeter and Bram Vervliet at the Universiteit van Amsterdam.


'/>"/>

Contact: Merel Kindt
M.Kindt@uva.nl
31-205-256-044-31205
Netherlands Organization for Scientific Research
Source:Eurekalert

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... VILNIUS, Lithuania , March 21, 2017 /PRNewswire/ ... identification and object recognition technologies, today announced the ... development kit (SDK), which provides improved facial recognition ... safety cameras on a single computer. The new ... algorithms to improve accuracy, and it utilizes a ...
(Date:3/22/2017)... , March 21, 2017 ... Cloud used by retailers such as 1-800-Flowers and ... platform — Product Recommendations and Replenishment. Using Optimove,s machine ... more personalized product and replenishment recommendations to their ... also on predictions of customer intent drawn from ...
(Date:3/22/2017)... Calif. , March 21, 2017 ... analytics company serving law enforcement agencies, announced today the ... as director of public safety business development. ... diversified law enforcement experience, including a focus on the ... In his most recent position, Mr. Sheridan served as ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... ... March 21, 2017 , ... Proper glycosylation ... on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or complement-dependent cytotoxicity, ... of therapeutic antibodies. , To meet this demand, the team at SCIEX ...
(Date:3/22/2017)... USA, and CARDIFF, UK (PRWEB) , ... March 21, 2017 , ... ... blood flow and tissue oxygenation, is being explored as a way to track the ... spectroscopy study on tonic pain activation by cold pressor test ,” published today in ...
(Date:3/22/2017)... 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a ... significant unmet medical needs, today announced Alexey ... present at the 5th Annual Cancer BioPartnering & ... to present to and meet with thought leaders ... companies as well as institutional investors. This event ...
(Date:3/20/2017)... ... March 20, 2017 , ... Avexegen Therapeutics Inc., an ... it has entered into an exclusive global license agreement with Children’s Hospital Los ... Enterocolitis (rare orphan disease) as well as Crohn’s Disease and Ulcerative Colitis. ...
Breaking Biology Technology: